Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
-
The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) worldwide may nowadays be regarded as a "twin" metabolic pandemic, causing the number of patients with the metabolic syndrome (MS) to rise rapidly. MS is a combination of several interrelated medical disorders such as obesity, T2DM, hypertension, dyslipidaemia etc. These conditions very frequently result in atherosclerosis, ischaemic heart disease, liver steatosis or even steatofibrosis. MS usually causes a significant worsening of the quality of life, often also leading to shortened life span. Bariatric, also referred to as metabolic (B-M), surgery currently represents a very powerful method for the treatment of morbid obesity and the metabolic syndrome. ⋯ Treatment options for the metabolic syndrome include bariatric-metabolic surgery, preferably using the mini-invasive laparoscopic method. These procedures are indicated primarily in morbidly obese patients with BMI > 40 kg/m2 after conservative therapy failure, or patients with severe obesity (BMI > 35 kg/m2) associated with serious circulatory, metabolic or mobility complications. Moreover, surgical treatment of T2DM has been proven to be possible in the last decade.